Skip to content
Open access

Generation and characterization of an isogenic gene-corrected iPSC line CARIMi009-A-1 from a Hutchinson-Gilford Progeria Syndrome (HGPS) patient with a heterozygous G608G mutation in the LMNA gene.

Aug 2026 · Stem Cell Research · Vol 95, pp. 104089 · 0 citations · 9 references
Medicine

TL;DR

This work generated and characterized the induced isogenic pluripotency stem cell control line generated by correcting the c.1824C > T mutation and excluded differences in genetic background while studying the pathophysiology of HGPS.

Abstract

Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare systemic laminopathy caused by a heterozygous point mutation in the LMNA gene encoding Lamin A/C (c.1824C > T, p.G608G). This synonymous mutation causes the production of a toxic form of Lamin A called Progerin. Integration of Progerin within the nuclear lamina disrupts cellular processes such as chromatin organization and gene transcription. Here we generated and characterized the induced isogenic pluripotency stem cell control line generated by correcting the c.1824C > T mutation. Used together with its parental line, this isogenic line excludes differences in genetic background while studying the pathophysiology of HGPS.

Read PDF

Similar papers

Open access Oct 2026

Generation and characterization of a human iPSC line (XACHi022-A) derived from an asymptomatic carrier of the GAA c.2051C > A (p.P684Q) variant.

Pompe disease is a lysosomal-store age disorder with GAA mutation. We collected a Pompe disease family with c.2051C > A (p.P684Q) and c.2024_2026 delACA (p. N675del) variants in GAA. In this study, we generated a human induced pluripotent stem cell (iPSC) line from an asymptomatic woman carrying c.2051C > A (p.P684Q) v...

Ya-Fei Zhou, Rui Zhou, Wen-Jun Huang et al. · 0 citations
Open access Sep 2026

Homology-directed CRISPR-Cas9 correction of the KRT5 p.E475G mutation in human iPSC line from a patient with severe epidermolysis bullosa simplex.

The generation of the human induced pluripotent stem cell line MLi002-A-1 is reported, an isogenic control derived from patient-specific MLi002-A line carrying the KRT5 c.1424A > G (p.E475G) mutation, which enables mutation-specific studies and in vitro modeling of epidermolysis bullosa simplex.

Ana Trobec, V. Lorrain, Dusko Ilic et al. · 0 citations
Open access Sep 2026

Generation of an induced pluripotent stem cell line, JHUi010-A, from an arrhythmogenic cardiomyopathy patient harboring pathogenic DSG2 variant c.2358delA.

We generated a human induced pluripotent stem cell (hiPSC) clonal line, JHUi010-A, from a 48-year-old female diagnosed with arrhythmogenic cardiomyopathy (ACM) carrying a heterozygous DSG2 c.2358delA variant using Sendai virus vectors expressing the Yamanaka factors. The line exhibits a normal karyotype, expresses stem...

Christianne J. Chua, D. DiSilvestre, Adriana Blazeski et al. · 0 citations
Open access Oct 2026

Generation of human induced pluripotent stem cell line (CMCi015-A) from a patient with nephronophthisis harboring compound heterozygous loss-of-function variants in the NPHP4 gene.

Nephronophthisis, an autosomal recessive ciliopathy, is a rare genetic kidney disorder characterized by progressive tubulointerstitial fibrosis, corticomedullary cyst formation, and progression to end-stage renal disease. Here, we established a human induced pluripotent stem cell (hiPSC) line from peripheral blood mono...

Jeeyoung Yoon, Y. Shin, Han-Bi Lee et al. · 0 citations
Open access Sep 2026

Establishment of a human induced pluripotent stem cell line, KMUGMCi011-A, from a patient bearing a frameshift mutation in the KMT2D gene leading Kabuki syndrome 1.

The peripheral blood mononuclear cells from a patient carrying frameshift mutation in the KMT2D gene were reprogrammed using the CytoTune-iPS2.0 Sendai Reprogramming Kit to allow proper in vitro disease modelling of Kabuki syndrome 1.

Hiroki Ura, Takako Hiyoshi, Y. Niida · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.